Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Do not order in the absence of a positive/equivocal ELISA screening test. Useful only when ordered during first 4 weeks of clinical symptoms and concurrently with IgG immunoblot.
MnemonicUnique test identifier.
LYME M WB
MethodologyProcess(es) used to perform the test.
Qualitative Immunoblot
PerformedDays of the week the test is performed.
Sun-Sat
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-2 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum separator tube.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
CSF or plasma. Contaminated, heat-inactivated, hemolyzed, or severely lipemic specimens.
Remarks
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Effective August 15, 2011
Negative
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, or 41 kDa. All other banding patterns are reported as negative.
Compliance Category
FDA
NoteAdditional information related to the test.
Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent EIA test and confirm equivocal and positive with immunoblot. Both IgM and IgG immunoblots should be performed on specimens less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot should be performed on specimens greater than 4 weeks after disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate immunoblot testing within 10 days.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.